Regorafenib shows significant survival gains in refractory liver cancer
Thursday, June 30, 2016 - 17:01
in Health & Medicine
Oral multikinase inhibitor regorafenib achieves significantly improved survival rates compared to placebo in patients with hepatocellular carcinoma, according to data from the phase III RESORCE trial (1), presented at the ESMO 18th World Congress of Gastrointestinal Cancer in Barcelona, Spain.